Limited treatment options are available for patients with a form of colorectal cancer that is driven by a mutated version of BRAF gene. However, results from a multi-centre clinical trial suggest that the cancer may respond to a combination of three targeted drugs. Professor Josep Tabernero, head of the medical oncology department at Vall d'Hebron University Hospital and director of the Vall d'Hebron Institute of Oncology, Barcelona, Spain, will tell the 26th EORTC-NCI-AACR ...Friday 21 November 2014
Combining Use of Three Drugs Better for Advanced Colorectal Cancer
Limited treatment options are available for patients with a form of colorectal cancer that is driven by a mutated version of BRAF gene. However, results from a multi-centre clinical trial suggest that the cancer may respond to a combination of three targeted drugs. Professor Josep Tabernero, head of the medical oncology department at Vall d'Hebron University Hospital and director of the Vall d'Hebron Institute of Oncology, Barcelona, Spain, will tell the 26th EORTC-NCI-AACR ...
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment